Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) — Stance & relative strength
LABT
Lakewood-Amedex Biotherapeutics Inc. Common Stock · Healthcare · Pharmaceutical Products
$3.51▲+2.33%
Neutral · stance 47
LABT is not confirmed as a leader.
3m RS is unavailable, Market Stance is 47
Lenses litMarket-wide RS; lit = leaderboard
TODAY'S READ · AS OF 2026-06-26
As of 2026-06-26, Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) has a 3-month relative strength percentile of — within the TickerStance CS+ADRC universe (~5,000 tickers). The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 17.8%, relative volume 3.16×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
LABTLakewood-Amedex Biotherapeutics Inc. Common Stock
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
LABT is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data.
Sector RS percentile is not available for Healthcare at this snapshot. Leading sector status (threshold: Healthcare RS ≥ 70th percentile) cannot be determined until the next sector RS pipeline run.
LABT currently shows a 20-day average daily range (ADR%) of 17.8%. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
TickerStance computes LABT's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what LABT has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.
LABT most recently filed a 10-Q covering FY26 Q1 with the SEC on 2026-05-22. TickerStance sources earnings data from SEC EDGAR XBRL submissions and updates the fundamentals panel daily. The Pro dossier shows eight quarters of EPS and revenue trend, operating margin history, and a composite earnings-quality rank.
§ Seasonality
Not enough history to compute monthly seasonality for LABT.